Drug Patents owned by Aaa Usa Novartis

1. Drug name - LOCAMETZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11369590 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 23, 2025

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 23 March, 2022

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
N/A POWDER;INTRAVENOUS Prescription

2. Drug name - PLUVICTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11318121 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

US10406240 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

US10398791 AAA USA NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

Market Authorisation Date: 23 March, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
27mCi/ML SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in